Upload
Featured Recent Articles Topics Login Upload

Search Results for ''

published presentations and documents on DocSlides.

Chemoprevention efficacy studies
Chemoprevention efficacy studies
by sylvia
(CPES). Charlotte Rasmussen. Pascal Ringwald. Guid...
Finish the sentences…
Finish the sentences…
by trish-goza
The cognitive approach believes the cause of addi...
INTRODUCTION TO DRUG REGULATORY SYSTEM.
INTRODUCTION TO DRUG REGULATORY SYSTEM.
by levi903
Drug Regulation means the control of Drug by regul...
International engagements by ADFMIDI in drug resistant malaria surveillance and elimination in Vi
International engagements by ADFMIDI in drug resistant malaria surveillance and elimination in Vi
by claire
Dr Mike Edstein (PhD) . Department of Drug Evaluat...
Center for Drug Evaluation and Research CDER ClinicalMedical
Center for Drug Evaluation and Research CDER ClinicalMedical
by pagi
Additional copies are available from: Office of Co...
Differentiating Drug-Seeking Behavior From Poorly Controlled Pain
Differentiating Drug-Seeking Behavior From Poorly Controlled Pain
by briana-ranney
Pain Prevalence in the United States . Opioid Pre...
Introduction to Antibody Drug Conjugates (ADC)
Introduction to Antibody Drug Conjugates (ADC)
by yoshiko-marsland
John Milne PhD, NIBRT. 20. th. . June 2014. Ehrl...
Chapter 5
Chapter 5
by pasty-toler
Pharmacodynamics. Pharmacodynamics. The study of ...
Phase I trials: A New era in
Phase I trials: A New era in
by mitsue-stanley
OnCology. drug development. Jan 22, 2015. Method...
Example of drug development
Example of drug development
by briana-ranney
Objectives of preclinical tests. Preclinical test...
Anjan Debnath, Ph.D
Anjan Debnath, Ph.D
by briana-ranney
.. Discovery of New Drug Leads for Rare Parasitic...
Evaluating and Enhancing Adherence to Medications
Evaluating and Enhancing Adherence to Medications
by liane-varnes
Bernard Vrijens, PhD. Chief Science Officer, MWV ...
The Thicket of Challenges in GPCR Molecular Pharmacology: P
The Thicket of Challenges in GPCR Molecular Pharmacology: P
by alida-meadow
o. pportunities . and. new hurdles . Ryan T. Str...
My Experiences as an FDA Statistician
My Experiences as an FDA Statistician
by aaron
Yeh-Fong Chen, Ph.D. . FDA/CDER/OB/DB3. CBA 2016-...
Legislative Advocacy: Why OTCs Go Over Parents’ Heads
Legislative Advocacy: Why OTCs Go Over Parents’ Heads
by test
Allison Baxterbeck. Elizabeth Chang. Amy . DiPila...
1 Structure and mandate of FDA
1 Structure and mandate of FDA
by sherrill-nordquist
Leonard Sacks. Office of Medical Policy. CDER, FD...
Clinical Pharmacology 2:
Clinical Pharmacology 2:
by myesha-ticknor
Clinical Pharmacology Considerations During Phase...
Additional copies are available from Office of Communications Divisi
Additional copies are available from Office of Communications Divisi
by catherine
TABLE OF CONTENTS BACKGROUND ........................
Design considerations for drug development in the era of immuno-oncology
Design considerations for drug development in the era of immuno-oncology
by isabella
Elizabeth Garrett-Mayer, PhD. Director, Division o...
Principles of Pharmacology:
Principles of Pharmacology:
by smith
Pharmacodynamics. Dennis Paul, Ph.D.. dpaul@lsuhsc...
Impact of Nanobiotechnology on the Future of Medicine (Nanomedicine):
Impact of Nanobiotechnology on the Future of Medicine (Nanomedicine):
by carla
The Road Toward Precision Medicine /. Case Studies...
ANTHELMINTICS Anticestodal Drugs
ANTHELMINTICS Anticestodal Drugs
by bety
…………………………………………â€...
The pharmaceutical industry
The pharmaceutical industry
by pasty-toler
March 27th 2014, University of Zurich . Fabienne ...
Biological Products: concepts, naming,
Biological Products: concepts, naming,
by faustina-dinatale
interchangeability,extrapolation. and safety. Dr...
Rectal Microbicides: Where We’re Heading
Rectal Microbicides: Where We’re Heading
by giovanna-bartolotta
Craig Hendrix, MD. Johns Hopkins University. Micr...
Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in
Long-term Tolerability and Efficacy of Evolocumab (AMG 145) in
by pamella-moone
Hyperlipidemic. Subjects: A 52 Week Phase 3 Dou...
The Downside of Publication
The Downside of Publication
by liane-varnes
Group 2: Jing Kai, . Nabilah. and Soon Guan. Pre...
Dabigatran in myocardial injury after noncardiac
Dabigatran in myocardial injury after noncardiac
by lois-ondreau
surgery. Dr. PJ Devereaux on behalf of . MANAGE I...
New Drugs The Good, The Bad,
New Drugs The Good, The Bad,
by jane-oiler
and the Worthless. Bill Origer MD. OAFP 2015. Dis...
Personality Personality – describes you as a person – how you are different from other people
Personality Personality – describes you as a person – how you are different from other people
by tatyana-admore
Traits – the terms we use to describe yourself ...
The Downside of Publication
The Downside of Publication
by karlyn-bohler
Group 2: Jing Kai, . Nabilah. and Soon Guan. Pre...
Stress, Anxiety & Depression:
Stress, Anxiety & Depression:
by giovanna-bartolotta
So What Do I Take?. Gary E. Foresman, MD. July 20...
The Bangkok Tenofovir Study
The Bangkok Tenofovir Study
by marina-yarberry
An HIV pre-exposure prophylaxis trial in Thailand...
The pharmaceutical industry
The pharmaceutical industry
by alida-meadow
March 27th 2014, University of Zurich . Fabienne ...
Pharmacology
Pharmacology
by cheryl-pisano
A Selective Overview. Carl Rosow, M.D., Ph.D.. Di...
Optimal Basket Designs for Efficacy Screening with Cherry-Picking
Optimal Basket Designs for Efficacy Screening with Cherry-Picking
by cheryl-pisano
Optimal Basket Designs for Efficacy Screening wit...
New Drugs The Good, The Bad,
New Drugs The Good, The Bad,
by loaiatdog
and the Worthless. Bill Origer MD. OAFP 2015. Disc...
Maine Department of Health and Human Services
Maine Department of Health and Human Services
by hazel
Office of MaineCare Services -Pharmacy Unit11 Stat...
ENGLISH ONLY FINAL EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Ge
ENGLISH ONLY FINAL EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Ge
by edolie
GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC...
European Medicines Agency 7 Westferry Circus Canary Wharf London E14 4
European Medicines Agency 7 Westferry Circus Canary Wharf London E14 4
by jasmine
ICH Topic E 10 Choice of Control Group in Clinical...